Reporter : Zachary Stieber , Li Yan / Editor : Lin Yan / https://www.epochtimes.com/gb/21/4/16/n12885023.htm / Translation, editing : Gan Yung Chyan, KUCINTA SETIA
Image : On April 7, 2021, at the West Wales General Hospital in Carmarthen, Wales, a healthcare professional holds a bottle of Moderna virus vaccine. (Jacob King-WPA Pool/Getty Images)
AstraZeneca's SARS-CoV-2 (CCP virus) vaccine is suspected of increasing the risk of blood clots. A new study found that people who received Pfizer or Moderna vaccines had similar rates of thrombosis to AstraZeneca recipients.
Researchers found that 4 out of 1 million patients developed cerebral venous thrombosis (CVT) symptoms after Pfizer or Moderna vaccines, while AstraZeneca vaccine recipients 5 people have this problem.
This observational study was initiated by scientists at Oxford University. They used electronic health records to compare three groups of people. The study subjects were either diagnosed with the Chinese Communist virus, or diagnosed with the flu, or vaccinated with Pfizer or Modena, to see the incidence of rare blood clots within two weeks.
"Although Moderna and Pfizer vaccines have similar thrombosis risk is a new discovery, we cannot conclude that the mRNA vaccine studied here is related to an increased risk of CVT. More samples are needed to solve this problem," the researchers wrote. Both Pfizer and Modena provide mRNA vaccines.
The research has not yet been peer reviewed.
Since last month, some people from different countries have experienced blood clot problems after being vaccinated with AstraZeneca. The vaccine is therefore subject to review by the EU drug regulatory agency.
The European Medicines Agency (EMA) concluded in early April that there was a "possible link" between the vaccine and blood clots, and recommended that AstraZeneca treat blood clots as a possible side effect of the vaccine.
This week, some recipients of the Johnson & Johnson vaccine experienced thrombosis after vaccination, triggering the suspension of the vaccine almost across the United States. US health officials say these problems are similar to those of AstraZeneca vaccine recipients.
However, US officials have also stated that neither Moderna nor Pfizer vaccines are related to CVT, and that this type of case is also accompanied by the problem of low platelets.
"To be very clear, these types of reactions-thrombosis combined with low platelets, are not seen in the licensed vaccines of Pfizer and Moderna." Rochelle Waugh, Director of the Centers for Disease Control and Prevention (CDC) Rochelle Walensky said in an online briefing this week.
Moderna and Pfizer also said that the assessment of safety data did not show that their own vaccines were linked to CVT or thrombotic events.
Infection and vaccination are both worrying about blood clots, the former is more risky
The new research is based on data recorded from TriNetX Analytics. This is a health records network that provides anonymous data from 59 medical institutions, most of which are in the United States.
The network has records of 81 million patients. Researchers looked at the records of 513,284 patients. Some of these patients were diagnosed with the CCP virus between January 20 and March 25, 2020. The second group made a flu diagnosis within the same time period, while the third group was vaccinated with Pfizer or Moderna virus vaccine.
The results found that compared with the second and third groups, people infected with COVID-19 had a CVT risk 8 to 10 times higher within two weeks after the diagnosis.
"We have reached two important conclusions. First, COVID-19 (the disease caused by SARS-CoV-2) has significantly increased the risk of CVT and increased the list of blood clots caused by this infection. Second, the risk posed by COVID-19 is greater .The vaccine (risk) seen is high, even for those under 30." Paul Harry, professor of psychiatry at the University of Oxford and head of the Translational Neurobiology Group at the University of Oxford Paul Harrison said in a statement.
"This should be taken into consideration when considering the risks and benefits of vaccination," he suggested.
No comments:
Post a Comment